On May 20, 2025, Zymeworks (ZYME, Financial) caught the attention of investors as TD Securities initiated coverage on the biotechnology company. Renowned analyst Yaron Weber from TD Securities assigned a "Buy" rating to ZYME. The stock, listed on the NASDAQ, is expected to benefit from this latest rating update.
While no specific price target was provided by TD Securities, the "Buy" recommendation itself suggests a positive outlook for ZYME's future performance in the market. Such ratings typically indicate that the analyst believes the company's stock price will rise and is worth purchasing at its current level.
ZYME, backed by this new analyst coverage, is poised to potentially experience increased interest from both current and prospective investors. This rating update serves as a focal point for stakeholders to take note of Zymeworks' position and potential in the biotech industry.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Zymeworks Inc (ZYME, Financial) is $22.39 with a high estimate of $30.00 and a low estimate of $13.00. The average target implies an upside of 81.73% from the current price of $12.32. More detailed estimate data can be found on the Zymeworks Inc (ZYME) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Zymeworks Inc's (ZYME, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Zymeworks Inc (ZYME, Financial) in one year is $21.72, suggesting a upside of 76.3% from the current price of $12.32. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Zymeworks Inc (ZYME) Summary page.
